首页> 外国专利> NOVEL BIFIDOBACTERIUM BREVE IDCC 4401 STRAIN AND ITS DEAD CELL ID-BBR4401 HAVING EXCELLENT ACID TOLERANCE AND BILE TOLERANCE AND PROPHYLACTIC OR THERAPEUTIC EFFECT ON DYSLIPIDEMIA

NOVEL BIFIDOBACTERIUM BREVE IDCC 4401 STRAIN AND ITS DEAD CELL ID-BBR4401 HAVING EXCELLENT ACID TOLERANCE AND BILE TOLERANCE AND PROPHYLACTIC OR THERAPEUTIC EFFECT ON DYSLIPIDEMIA

机译:新的双歧杆菌BREVE IDCC 4401菌株及其死电池ID-BBR4401具有优异的耐酸性和胆汁耐受性和对血脂血症的预防或治疗效果

摘要

The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and its dead cell ID-BBR4401, which are superb in acid tolerance and bile tolerance and have a preventive or therapeutic effect on dyslipidemia. Having not only an excellent effect of reducing a cholesterol level in the body but also a very high level of acid tolerance and bile tolerance in contrast to previously known B. breve, the novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) of the present invention well exhibits the functionality that the strain has in the digestive duct of animals (especially humans), has an excellent growth potential, and provides sustainable and effective functionality of reducing a level of cholesterol in vivo.
机译:本发明涉及一种新型双歧杆菌BREVE IDCC 4401菌株(登录数:KCTC13169BP)及其死池ID-BBR4401,其在耐酸性和胆耐受中均匀,对血脂血症具有预防或治疗作用。 与先前已知的B. Breve,新的双歧杆菌Breve IDCC 4401应变(登录号:KCTC13169BP),不仅具有减少体内的胆固醇水平,还具有非常高水平的酸性耐受性和胆耐受性。 本发明良好的表现出菌株在动物的消化管(特别是人)中具有优异的生长潜力,并提供可持续和有效的函数降低体内胆固醇水平的功能。

著录项

  • 公开/公告号WO2022005035A1

    专利类型

  • 公开/公告日2022-01-06

    原文格式PDF

  • 申请/专利权人 IL DONG PHARMACEUTICAL CO. LTD.;

    申请/专利号WO2021KR07117

  • 发明设计人 KIM MIN-GOO;LEE DON-GIL;KIM TAE-YOON;

    申请日2021-06-08

  • 分类号C12N1/20;A61K35/74;A61P3/06;A23L33/135;A23K10/10;C12R1/01;

  • 国家 KR

  • 入库时间 2022-08-24 23:16:36

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号